Ultragenyx Pharmaceutical (RARE) Rating Increased to Buy at BidaskClub
Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
A number of other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Cowen reaffirmed a “buy” rating and set a $69.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 26th. Raymond James reaffirmed an “outperform” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 22nd. Citigroup upped their price target on shares of Ultragenyx Pharmaceutical from $54.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 21st. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 20th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $76.16.
NASDAQ:RARE opened at $68.27 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The firm has a market cap of $3.50 billion, a PE ratio of -9.24 and a beta of 2.21.
Several institutional investors have recently added to or reduced their stakes in RARE. Capital International Investors boosted its position in shares of Ultragenyx Pharmaceutical by 20.9% in the 3rd quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock worth $332,834,000 after buying an additional 755,127 shares in the last quarter. Capital World Investors lifted its holdings in Ultragenyx Pharmaceutical by 75.8% in the 3rd quarter. Capital World Investors now owns 1,461,390 shares of the biopharmaceutical company’s stock valued at $111,563,000 after purchasing an additional 630,088 shares in the last quarter. Norges Bank purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $16,047,000. D. E. Shaw & Co. Inc. lifted its holdings in Ultragenyx Pharmaceutical by 5,859.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 321,834 shares of the biopharmaceutical company’s stock valued at $13,993,000 after purchasing an additional 316,434 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $20,045,000. Institutional investors and hedge funds own 99.20% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.